475. Psilocin pharmacokinetics and exposure-response relationships in Japanese patients with treatment-resistant depression receiving psilocybin therapy: an open-label study
The International Journal of Neuropsychopharmacology September 1, 2026 K Kusudo, K Yonezawa, S Tomiyama et al.
Abstract Background Psilocybin, a prodrug metabolized to psilocin, a serotonin 2A receptor agonist, has reemerged as a promising therapeutic option for treatment-resistant depression (TRD). Clinical trials conducted mainly in North America and Europe have demonstrated that psilocybin administered with psychological support can produce rapid and sustained antidepressant effects with favorable...